Quebec Launches First-Ever Genomic Medicine Policy to Advance Precision Medicine Across the Province
核心洞察
Quebec has released its inaugural Politique québécoise en médecine génomique, a framework for ethical, equitable, and sustainable expansion of genomic medicine province-wide.
The policy establishes standards, infrastructure, and coordination to move genomic testing from specialized centers into routine clinical practice across Quebec.
Clinicians will be better equipped to anticipate disease risk, refine diagnoses, and deliver personalized treatments based on patients' molecular and genomic characteristics.
The Government of Quebec has released its first-ever Politique québécoise en médecine génomique (Quebec Genomic Medicine Policy), a landmark framework dedicated to the ethical, equitable, and sustainable expansion of genomic medicine across the province. The policy represents the culmination of several years of collaboration among clinicians, researchers, and patient groups, and positions Quebec at the forefront of integrating genomic discoveries into everyday clinical care.
The policy will help clinicians better anticipate disease risk and refine diagnoses for patients and their families, marking a decisive shift from genomic testing being confined to a handful of specialized centers toward routine, equitable practice throughout Quebec.
Dr. Alan Spatz, medical director of Optilab Montreal-MUHC and president of the Cancer (搜索) committee of the Réseau québécois de diagnostic moléculaire (搜索) (RQDM), was among a small group of experts invited by the Ministère de la Santé et des Services sociaux (搜索) (MSSS) to help shape the policy. "This policy is a decisive step for Quebec. It gives our laboratories the standards, the infrastructure, and the coordination we need to move genomic testing from a handful of specialized centres into routine, equitable practice across the province, which means faster answers and more personalized care for patients wherever they live," said Dr. Spatz.
Translating Genomic Discoveries into Clinical Practice
Patients are already benefiting from genomic discoveries translated into everyday care at institutions such as the McGill University Health Centre (MUHC). A research team led by Dr. Julia Burnier is advancing liquid biopsy (搜索) approaches that use minimally invasive samples, including blood and saliva, to detect and analyze cancer (搜索)-derived DNA. These technologies hold the potential to transform how cancer is detected and how patients are monitored throughout their care journey.
In Quebec, some liquid biopsy (搜索) tests are already available clinically, while research teams such as Dr. Burnier's are developing new approaches aimed at expanding their use. "Genomic medicine is allowing us to look beyond symptoms and better understand the underlying biology of each patient's condition," explained Dr. Burnier. "We have the opportunity to detect disease earlier by using genomic information, and now, the priority is to ensure that these advances move from research into practice."
Through international collaborations, the MUHC has established itself as a leading voice in genomic medicine, driven substantially by work underway in the OPTILAB Division of Molecular Genetics. Continued participation in the RQDM reflects a shared vision: accounting for fine-grained variations in a person's DNA to offer more tailored therapies and enable more nuanced conversations with patients and families.
Precision Medicine in Oncology
The policy carries particular significance for oncology, where precision medicine is reshaping treatment paradigms. Dr. Ramy Saleh, an MUHC oncologist, emphasized the transformative potential: "Precision medicine is transforming oncology by allowing us to move beyond a one-size-fits-all approach. By understanding the molecular and genomic characteristics of each patient's cancer (搜索), we can select treatments more intelligently, avoid ineffective therapies, and offer patients and their families clearer, more personalized guidance."
Dr. Saleh added that the policy represents "an important step toward ensuring that these advances are accessible to patients across Quebec, regardless of where they receive their care."
Addressing Practical Challenges
The Quebec Genomic Medicine Policy tackles the practical challenges of bringing genomic medicine to the entire population. Key areas addressed include workforce training, laboratory capacity, equitable access to genomic services, and each person's right to decide whether to learn about hereditary risks that may affect them. The framework provides the standards and coordination necessary to ensure that genomic medicine's benefits reach all Quebecers, not just those treated at specialized academic centers.